Back to top
more

CytomX Therapeutics (CTMX)

(Delayed Data from NSDQ)

$1.05 USD

1.05
1,448,351

+0.05 (5.45%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $1.04 -0.01 (-0.95%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You May Invest in Puma Biotechnology (PBYI) Stock

by Zacks Equity Research

Here, we discuss some reasons why investing in Puma Biotechnology (PBYI) stock now may turn out to be a more prudent move than ever.

CytomX Therapeutics (CTMX) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

CytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for CytomX Therapeutics (CTMX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 89.47% and 42.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 40.91% and 4.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Add ImmunoGen (IMGN) to Your Portfolio Now

by Zacks Equity Research

ImmunoGen's (IMGN) recently launched drug, Elahere, is expected to generate incremental revenues for the company and boost its top-line growth in the next few years.

CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 68.75% and 5.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Codexis (CDXS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of -17.24% and 11.34%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Certara, Inc. (CERT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Certara, Inc. (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will CytomX Therapeutics (CTMX) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -100% and 94.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 14.29% and 4.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

NeoGenomics (NEO) delivered earnings and revenue surprises of 60% and 6.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Beyond Air, Inc. (XAIR) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of -2.38% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CytomX (CTMX) Up 55% on Strategic Partnership With Moderna

by Zacks Equity Research

CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.

Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update

by Zacks Equity Research

Updates from CTMX and APLS are the key highlights from the biotech sector during the past week.

CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron

by Zacks Equity Research

CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.

CytomX Therapeutics (CTMX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -9.38% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of -12.37% and 4.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -2.78% and 1.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NeoGenomics (NEO) Surges 6.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

CytomX Therapeutics (CTMX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -5.71% and 21.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -60% and 32.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?